Press Detail

/

PRESS RELEASE


Biotest: Voluntary recall of human albumin

- Already quarantined batches of human albumin are recalled

- Consequences of the one-time effect on Sales and EBIT are currently being evaluated

- As a precaution, guidance is being reduced

Dreieich, 26 April 2017 Today, Biotest has informed its customers about the recall of several batches of human albumin. The batches in question had already been quarantined by Biotest as a precautionary measure on 13 April 2017. Since that day, no affected product had been used. By recalling the affected products, Biotest ensures that all products are being returned.

An equipment failure in the production of an albumin intermediate gave reason for this action. The equipment failure has already been fixed.

The recall is performed in close co-operation with the regulatory authorities. Further information is available on our website: http://www.biotest.com/de/en/products.cfm

After repairing of the equipment failure, the original production range has already been reached again. This one-time effect will only impact the fiscal year 2017. Consequences on Sales and EBIT are currently being evaluated. As a precaution, Biotest reduces its Sales guidance from low single-digit growth rate to the level of the previous year and its EBIT guidance of EUR46 to EUR48 million by EUR25 to EUR30 million.

About Human Albumin
Albumin is used in particular in intensive care medicine and acute care. Patients with extensive blood or fluid loss, due to burns among other things, have too little of the important proteins in their blood. This protein loss is compensated by administering Albumin. Albumin is also used for volume replacement in cases of blood poisoning. Unlike synthetically manufactured drugs, Albumin produced from human plasma offers particularly good tolerability. It is also the most important protein carrier in the blood for binding and removing (harmful) substances from the vascular system.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.